hsa-mir-642a: Hsa-mir-642a is a primate-specific tumor suppressor miRNA that has been found to be significantly associated with survival time and prognosis in patients with cutaneous squamous cell carcinoma (CSCC) [PMC5841789]. It has been reported that the presence of the variant C allele of TLR4 rs11536889 loses a motif binding for hsa-mir-642a [PMC5356775]. In a study on CSCC, hsa-mir-642a was identified as part of a miRNA signature that could be used as a valuable tool in guiding treatment decisions for CSCC [PMC5841789]. Hsa-mir-642a was found to be associated with the survival time of CSCC patients and could serve as a diagnostic and prognostic marker for the disease [PMC5841789]. It has also been observed that hsa-mir-642a is overexpressed in pediatric embryonal central nervous system neoplasms, which is considered to be a prognostic parameter for patients [PMC5841789]. Hsa-mir-642a has been shown to target cryptochrome circadian clock 2 (CRY2) and its abnormal expression in myeloma cell lines leads to dedifferentiation of myeloma cells [PMC5841789]. Additionally, hsa-mir-642a is differentially expressed in lung cancer cells and its expression, along with hsa-mir-378c, can be detected in blood samples to predict the survival time of CSCC patients, potentially improving clinical outcomes [PMC5841789]. Hsa-mir-642a has also been associated with cervical cancer prognosis and identified as part of miRNA signatures strongly associated with survival after multi-factor CoxPH regression model analysis [PMC5841789]. Furthermore, it has been found that underexpressed miRNAs including hsa-mir-642a are associated with the circadian entrainment pathway and have common predicted target genes in KEGG pathways [PMC7794682].